APA-话题@MedSci

#APA#

153篇内容 | 3636人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1338135, encodeId=7d58133813503, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=AACR 2015：女性患者福音！Olaparib联合Carboplatin对卵巢、乳腺癌初显疗效, objectType=article, longId=49756, objectId=704249e564a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=704249e564a, replyNumber=0, likeNumber=69, createdTime=2015-04-24, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=704249e564a, moduleTitle=AACR 2015：女性患者福音！Olaparib联合Carboplatin对卵巢、乳腺癌初显疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=704249e564a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338134, encodeId=1237133813420, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=APASL 2015 重要议题抢先看！, objectType=article, longId=47698, objectId=034f4e69817, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=034f4e69817, replyNumber=0, likeNumber=0, createdTime=2015-03-05, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=034f4e69817, moduleTitle=APASL 2015 重要议题抢先看！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=034f4e69817)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338133, encodeId=997b133813354, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=重症监护室死亡率与APACHE II评分公式, objectType=article, longId=44652, objectId=61b844652ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61b844652ac, replyNumber=0, likeNumber=32, createdTime=2014-12-27, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61b844652ac, moduleTitle=重症监护室死亡率与APACHE II评分公式, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61b844652ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338132, encodeId=f051133813218, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=欧盟医药管理部门将表决是否加速阿斯利康卵巢癌药物olaparib审批流程, objectType=article, longId=41335, objectId=956741335b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=956741335b1, replyNumber=0, likeNumber=81, createdTime=2014-10-18, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=956741335b1, moduleTitle=欧盟医药管理部门将表决是否加速阿斯利康卵巢癌药物olaparib审批流程, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=956741335b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338131, encodeId=fddb133813163, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=EASD 2014：二甲双胍联合SAXA和DAPA改善血糖更佳, objectType=article, longId=40283, objectId=fd3e4028394, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd3e4028394, replyNumber=0, likeNumber=97, createdTime=2014-09-17, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd3e4028394, moduleTitle=EASD 2014：二甲双胍联合SAXA和DAPA改善血糖更佳, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd3e4028394)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338130, encodeId=574213381301b, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=AHJ：vorapaxar治疗伴PAD急性冠脉综合征患者的效果, objectType=article, longId=37754, objectId=59f43e75402, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59f43e75402, replyNumber=0, likeNumber=50, createdTime=2014-07-13, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59f43e75402, moduleTitle=AHJ：vorapaxar治疗伴PAD急性冠脉综合征患者的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59f43e75402)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338129, encodeId=d64e133812911, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=阿斯利康“死去”的抗癌药物Olaparib“复活”, objectType=article, longId=37141, objectId=ef013e1416c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef013e1416c, replyNumber=0, likeNumber=53, createdTime=2014-06-29, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef013e1416c, moduleTitle=阿斯利康“死去”的抗癌药物Olaparib“复活”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ef013e1416c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338128, encodeId=d5a9133812870, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=阿斯利康抗癌药olaparib上市之路坎坷不平, objectType=article, longId=37015, objectId=47733e0152d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47733e0152d, replyNumber=0, likeNumber=60, createdTime=2014-06-27, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47733e0152d, moduleTitle=阿斯利康抗癌药olaparib上市之路坎坷不平, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47733e0152d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338127, encodeId=1934133812e0c, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=GSK与Galapagos的银屑病药物GSK2586184中期试验达终点, objectType=article, longId=33653, objectId=fa033365384, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa033365384, replyNumber=0, likeNumber=65, createdTime=2014-04-23, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa033365384, moduleTitle=GSK与Galapagos的银屑病药物GSK2586184中期试验达终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa033365384)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338126, encodeId=d442133812647, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=APASL 2014：中国植物药—肝纤维化治疗的新方法, objectType=article, longId=32300, objectId=ecf3323007c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ecf3323007c, replyNumber=0, likeNumber=73, createdTime=2014-03-26, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ecf3323007c, moduleTitle=APASL 2014：中国植物药—肝纤维化治疗的新方法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ecf3323007c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338125, encodeId=4bbc13381259b, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=APASL 2014：乙肝的治疗终点及其实现方法, objectType=article, longId=32144, objectId=87f83214456, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=87f83214456, replyNumber=0, likeNumber=65, createdTime=2014-03-21, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=87f83214456, moduleTitle=APASL 2014：乙肝的治疗终点及其实现方法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=87f83214456)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338124, encodeId=c8c8133812477, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=阿斯利康启动olaparib III期SOLO项目, objectType=article, longId=24122, objectId=04fd241222d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04fd241222d, replyNumber=0, likeNumber=55, createdTime=2013-09-11, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04fd241222d, moduleTitle=阿斯利康启动olaparib III期SOLO项目, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04fd241222d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338123, encodeId=d0fa133812363, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=APA 2013：孕期高脂多糖饮食或致子女酗酒、超重, objectType=article, longId=22722, objectId=2e8a22e223e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e8a22e223e, replyNumber=0, likeNumber=76, createdTime=2013-08-08, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e8a22e223e, moduleTitle=APA 2013：孕期高脂多糖饮食或致子女酗酒、超重, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e8a22e223e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338122, encodeId=ecf61338122dc, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=北京大学人民医院魏来教授当选亚太肝病学会（APASL）执行委员, objectType=article, longId=21994, objectId=beac21994a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=beac21994a7, replyNumber=0, likeNumber=70, createdTime=2013-07-26, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=beac21994a7, moduleTitle=北京大学人民医院魏来教授当选亚太肝病学会（APASL）执行委员, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=beac21994a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338121, encodeId=f6241338121af, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=APASL 2013：恩替卡韦长期抗病毒治疗降低HCC风险, objectType=article, longId=21705, objectId=738021e0540, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=738021e0540, replyNumber=0, likeNumber=82, createdTime=2013-07-21, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=738021e0540, moduleTitle=APASL 2013：恩替卡韦长期抗病毒治疗降低HCC风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=738021e0540)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338120, encodeId=a18c13381205e, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=Lancet Oncol：Niraparib治疗BRCA突变型散发肿瘤患者安全有效, objectType=article, longId=21400, objectId=ce8f21400c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce8f21400c7, replyNumber=0, likeNumber=56, createdTime=2013-07-17, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce8f21400c7, moduleTitle=Lancet Oncol：Niraparib治疗BRCA突变型散发肿瘤患者安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce8f21400c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338119, encodeId=67991338119b8, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=2013亚太肝脏研究学会（APASL）主席推荐的重点报告, objectType=article, longId=21330, objectId=60392133007, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=60392133007, replyNumber=0, likeNumber=71, createdTime=2013-07-15, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=60392133007, moduleTitle=2013亚太肝脏研究学会（APASL）主席推荐的重点报告, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=60392133007)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338118, encodeId=838013381184a, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=ADA 2013：达格列净（Dapagliflozin ）单药治疗未曾用药的T2DM安全有效, objectType=article, longId=20758, objectId=adc720e580f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=adc720e580f, replyNumber=0, likeNumber=76, createdTime=2013-07-03, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=adc720e580f, moduleTitle=ADA 2013：达格列净（Dapagliflozin ）单药治疗未曾用药的T2DM安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=adc720e580f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338117, encodeId=1f33133811ebf, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=APA：米氮平在抑郁症治疗中的作用, objectType=article, longId=18537, objectId=bd1d1853ec1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bd1d1853ec1, replyNumber=0, likeNumber=91, createdTime=2013-05-12, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bd1d1853ec1, moduleTitle=APA：米氮平在抑郁症治疗中的作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bd1d1853ec1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338116, encodeId=a3ab133811629, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=APA：医患关系与抗抑郁治疗, objectType=article, longId=17609, objectId=39ad1e609e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39ad1e609e3, replyNumber=0, likeNumber=70, createdTime=2013-04-21, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39ad1e609e3, moduleTitle=APA：医患关系与抗抑郁治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39ad1e609e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

APA

2020-05-29

zhaojie88 (审核中...)

前往app查看评论内容

#APA#

AACR 2015：女性患者福音！Olaparib联合Carboplatin对卵巢、乳腺癌初显疗效

2015-04-24

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

APASL 2015 重要议题抢先看！

2015-03-05

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

重症监护室死亡率与APACHE II评分公式

2014-12-27

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

欧盟医药管理部门将表决是否加速阿斯利康卵巢癌药物olaparib审批流程

2014-10-18

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

EASD 2014：二甲双胍联合SAXA和DAPA改善血糖更佳

2014-09-17

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

AHJ：vorapaxar治疗伴PAD急性冠脉综合征患者的效果

2014-07-13

仁心济世 (审核中...)

前往app查看评论内容

#APA#

阿斯利康“死去”的抗癌药物Olaparib“复活”

2014-06-29

仁心济世 (审核中...)

前往app查看评论内容

#APA#

阿斯利康抗癌药olaparib上市之路坎坷不平

2014-06-27

仁心济世 (审核中...)

前往app查看评论内容

#APA#

GSK与Galapagos的银屑病药物GSK2586184中期试验达终点

2014-04-23

仁心济世 (审核中...)

前往app查看评论内容

#APA#

APASL 2014：中国植物药—肝纤维化治疗的新方法

2014-03-26

仁心济世 (审核中...)

前往app查看评论内容

#APA#

APASL 2014：乙肝的治疗终点及其实现方法

2014-03-21

仁心济世 (审核中...)

前往app查看评论内容

#APA#

阿斯利康启动olaparib III期SOLO项目

2013-09-11

仁心济世 (审核中...)

前往app查看评论内容

#APA#

APA 2013：孕期高脂多糖饮食或致子女酗酒、超重

2013-08-08

仁心济世 (审核中...)

前往app查看评论内容

#APA#

北京大学人民医院魏来教授当选亚太肝病学会（APASL）执行委员

2013-07-26

仁心济世 (审核中...)

前往app查看评论内容

#APA#

APASL 2013：恩替卡韦长期抗病毒治疗降低HCC风险

2013-07-21

仁心济世 (审核中...)

前往app查看评论内容

#APA#

Lancet Oncol：Niraparib治疗BRCA突变型散发肿瘤患者安全有效

2013-07-17

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

2013亚太肝脏研究学会（APASL）主席推荐的重点报告

2013-07-15

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

ADA 2013：达格列净（Dapagliflozin ）单药治疗未曾用药的T2DM安全有效

2013-07-03

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

APA：米氮平在抑郁症治疗中的作用

2013-05-12

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

APA：医患关系与抗抑郁治疗

2013-04-21

科室
- - 订阅+
  - 更多科室
工具
服务